ElMindA develops the Brain Network Activation (BNA™) system, a non-invasive multi-channel EEG-ERP platform that applies advanced signal processing and machine-learning to map neuronal networks during specific brain functions. The technology is positioned to support clinical decision making for conditions such as concussion, Alzheimer’s, Parkinson’s, depression, ADHD and other brain disorders. BNA received FDA clearance in 2014 for a specific indication and holds a CE Mark in Europe. The company plans to use new funding to continue technical advancement of BNA and to drive commercial and clinical adoption. BNA is already available to healthcare providers at 15 locations across eight U.S. cities. ElMindA was founded in 2006 and is headquartered in Chicago.

Total raised

$28M

Funding rounds

1

Latest round

Series C

Latest activity

Nov 2015